-TheWire.in The government appears bent on decisively abandoning the earlier consensus of adherence to public health goals. In what is widely being hailed as an extraordinary victory for the multinational pharmaceutical industry over the Indian government, the US-India Business Council (USIBC), in its submission to the United States Trade Representative (USTR), reports that the Indian government has “privately assured” the industry that it would not use compulsory licences (CLs) for commercial purposes....

-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...

-The Times of India The man who has been appointed the chief economic advisor to the government of India, Arvind Subramanian, was until recently urging the US to initiate disputes against India before the World Trade Organisation and also seeking changes in provisions within Indian patent law aimed at preventing frivolous patenting and preventing pharma companies from getting extensions on patents by tweaking existing drugs and passing them off as innovations. Subramanian...

-The Times of India A paragraph buried in the US-India joint statement, which talks of establishing an annual high-level Intellectual Property (IP) working group as part of the Trade Policy Forum, has made health activists across the world apprehensive that the Modi government might be bending to US pressure to change its patent laws. Several health policy experts and activists have issued statements urging India not to give in to US...

-PTI India however maintained that the India Patent Act was in accordance with the TRIPS Agreement & the Paris Convention The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied. "PhRMA remains concerned about the deteriorating intellectual property environment in India," Mark Grayson, PhRMA spokesman told PTI. The remarks by PhRMA or Pharmaceutical Research and Manufacturers of America, representing America's...